Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) last reported results for the quarter ended Jun 2026, with sales of ₹82 crore and net profit of ₹13 crore. The next scheduled event is a merger acquisition on 1 Nov 2026. The stock last traded at ₹226, a market capitalisation of ₹1,495 crore, on a P/E of 31.8. Over the past 52 weeks the stock has ranged between ₹155 and ₹265. Figures are as of 9 Oct 2026 and are not real time.
Jagsonpal Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹226
- Market cap
- ₹1,495 cr
- Stock P/E
- 31.8
- Book value
- ₹41.2
- ROE
- 17.3%
- ROCE
- 22.7%
- Dividend yield
- 1.77%
- 52w high / low
- 265/155
Metrics as of 9 Oct 2026. Not real time.
Track Jagsonpal Pharmaceuticals Ltd
Cruxal reads every Jagsonpal Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Jagsonpal Pharmaceuticals Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- 4%
- 10 Years
- 30%
- 5 Years
- 21%
- 3 Years
- 16%
- TTM
- 10%
- 10 Years
- 29%
- 5 Years
- 30%
- 3 Years
- 11%
- 1 Year
- 5%
- 10 Years
- 11%
- 5 Years
- 16%
- 3 Years
- 15%
- Last Year
- 17%
Jagsonpal Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹82 cr, up 7.9% from ₹76 cr a year earlier. Net profit was ₹13 cr, up 18.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 |
| Expenses | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 |
| Operating profit | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 |
| OPM % | 22% | 21% | 15% | 19% | 22% | 22% | 17% | 21% |
| Other income | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 |
| Tax % | 25% | 17% | 24% | 25% | 25% | 25% | 25% | 25% |
| Net profit | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 |
| EPS (₹) | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 | 2.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Jagsonpal Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 | 294 |
| Operating profit | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 58 | 61 |
| OPM % | 4.0% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% | 21% |
| Net profit | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 43 | 45 |
| EPS (₹) | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 6.43 | 6.84 |
TTM is the trailing twelve months to the most recent quarter.
Jagsonpal Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 263 |
| Borrowings | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 8 |
| Other liabilities | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 32 |
| Total liabilities | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 |
| Fixed assets | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 85 |
| CWIP | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
| Other assets | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 231 |
| Total assets | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 |
As reported by the company. Total assets equal total liabilities by construction.
Jagsonpal Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3 | -2 | 31 | 11 | 28 | 7 | 47 | 35 | 55 | 47 |
| Cash from investing | 41 | -3 | -1 | -11 | -2 | -26 | -58 | -25 | -45 | -36 |
| Cash from financing | -34 | -1 | -6 | -1 | -7 | -18 | -0 | -9 | -12 | -12 |
| Net cash flow | 5 | -6 | 24 | -0 | 19 | -36 | -11 | 2 | -2 | -1 |
| Free cash flow | 40 | -5 | 30 | 12 | 28 | 6 | 48 | 35 | 90 | 47 |
| CFO / operating profit | -6% | 14% | 311% | 150% | 164% | 54% | 158% | 189% | 124% | 101% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Jagsonpal Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% | 23% |
| Debtor days | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 | 22 |
| Inventory days | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 | 51 |
| Days payable | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 | 40 |
| Cash conversion cycle | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 | 33 |
| Working capital days | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 | 11 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Jagsonpal Pharmaceuticals Ltd shareholding pattern
Promoters held 69.06% at Jun 2026, up from 67.65% at Jun 2025. FIIs 2.30% and DIIs 0.62%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 67.98% | 67.82% | 67.77% | 67.65% | 67.54% | 67.39% | 67.89% | 69.06% |
| FIIs | 2.30% | 2.10% | 2.10% | 2.17% | 2.12% | 2.12% | 2.44% | 2.30% |
| DIIs | 0.11% | 0.00% | 0.00% | 0.05% | 0.08% | 0.15% | 0.22% | 0.62% |
| Public | 29.63% | 30.10% | 30.11% | 30.12% | 30.25% | 30.34% | 29.44% | 28.04% |
| No. of shareholders | 15,633 | 18,471 | 21,085 | 22,899 | 24,653 | 24,895 | 26,264 | 24,181 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Jagsonpal Pharmaceuticals Ltd events
The next scheduled event is a merger acquisition on 1 Nov 2026.
- Merger acquisitionAcquisition of Wellness Portfolio of Group Pharmaceuticals Limited
See the full results calendar for every Indian company reporting in the next 30 days.
Jagsonpal Pharmaceuticals Ltd corporate filings
- Certificate in terms of Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026Company Updatelow impact
- Jagsonpal Pharmaceuticals completes strategic acquisition of Group Pharmaceuticals' Wellness Portfolio, signaling a significant expansion into the consumer wellness and specialty pharma segments.Company Updatehigh impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has announced the consummation of its acquisition of 85% stake…
Read the full analysis - No financial or strategic corporate action disclosed; recent regulatory and share transfer notices issuedCompany Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has issued multiple regulatory disclosures including transfer…
Read the full analysis - Jagsonpal Pharmaceuticals Allots 101,825 Equity Shares under ESOP 2022Company Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals announced the allotment of 101,825 equity shares under its…
Read the full analysis - Closure of Trading window for the quarter and six months ended September 30, 2026.Insider Trading / SASTlow impact
- Jagsonpal Pharmaceuticals to acquire Wellness Portfolio of Group Pharmaceuticals for up to 46.7 croreCompany Updatehigh impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement to…
Read the full analysis - Jagsonpal Pharmaceuticals Limited announces successful conclusion of 47th Annual General Meeting and voting resultsAGM/EGMlow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited has successfully concluded its 47th Annual General…
Read the full analysis - Jagsonpal Pharmaceuticals Ltd concludes 47th AGM; approves financial statements, dividend, and board appointmentsAGM/EGMlow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Ltd has successfully concluded its 47th Annual General Meeting…
Read the full analysis - Jagsonpal Pharmaceuticals Ltd announces dispatch of 47th AGM notice and e-voting detailsCompany Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has completed the newspaper publication regarding the dispatch…
Read the full analysis - Jagsonpal Pharmaceuticals Limited Announces 47th AGM, Dividend Payout, and Strategic Acquisition of Aequitas HealthcareAGM/EGMhigh impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited has scheduled its 47th Annual General Meeting for…
Read the full analysis - Jagsonpal Pharmaceuticals Ltd files Business Responsibility and Sustainability Report (BRSR) for FY2026Otherslow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has submitted its Business Responsibility and Sustainability…
Read the full analysis - Jagsonpal Pharmaceuticals Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Jagsonpal Pharmaceuticals Ltd releases Annual Report for FY 2025-26Company Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has provided the web link for its Annual Report for the…
Read the full analysis - Jagsonpal Pharmaceuticals allots 27,950 equity shares under ESOP 2022Company Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited has announced the allotment of 27,950 equity shares to…
Read the full analysis - Jagsonpal Pharmaceuticals Ltd schedules 47th Annual General Meeting for September 18, 2026Company Updatelow impact
Cruxal's analysis: Jagsonpal Pharmaceuticals has issued a newspaper advertisement confirming that its 47th…
Read the full analysis - Jagsonpal Pharmaceuticals Reports Strong Q1 FY27 Growth, 21% EBITDA Jump, Strategic Aequitas Acquisition, and INR 40 Crore BuybackCompany Updatehigh impact
Cruxal's analysis: Jagsonpal Pharmaceuticals Limited delivered a robust Q1 FY27, with revenue from…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.